scholarly journals Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma

2016 ◽  
Vol 8 (9) ◽  
pp. 2464-2472 ◽  
Author(s):  
Zu-Yang Yuan ◽  
Shu-Geng Gao ◽  
Ju-Wei Mu ◽  
Qi Xue ◽  
You-Sheng Mao ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Prognostic Value ◽  
Thymic Carcinoma ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Preoperative Serum

scholarly journals Prognostic value of preoperative serum lactate dehydrogenase levels for resectable gastric cancer and prognostic nomograms

Oncotarget ◽  
2016 ◽  
Vol 7 (26) ◽  
pp. 39945-39956 ◽  
Author(s):  
Zi-Xian Wang ◽  
Lu-Ping Yang ◽  
Miao-Zhen Qiu ◽  
Zhi-Qiang Wang ◽  
Yi-Xin Zhou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lactate Dehydrogenase ◽  
Prognostic Value ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Preoperative Serum ◽  
Resectable Gastric Cancer

scholarly journals Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (11) ◽  
pp. e0166482 ◽  
Author(s):  
Jie Shen ◽  
Zhen Chen ◽  
Qianfeng Zhuang ◽  
Min Fan ◽  
Tao Ding ◽  
...  
Keyword(s):  
Systematic Review ◽  
Renal Cell Carcinoma ◽  
Lactate Dehydrogenase ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase

scholarly journals 99: Prognostic Value of Pre-Treatment Serum Lactate Dehydrogenase in HPV-Related and HPV-Unrelated Oropharyngeal Cancer

2016 ◽  
Vol 120 ◽  
pp. S38-S39
Author(s):  
Shao Hui Sophie Huang ◽  
Scott V. Bratman ◽  
Jie Su ◽  
Li Tong ◽  
John Kim ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Oropharyngeal Cancer ◽  
Prognostic Value ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Pre Treatment

Prognostic value of serum lactate dehydrogenase in symptomatic multiple myeloma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8093-8093 ◽  
Author(s):  
Krina K. Patel ◽  
Robert Z. Orlowski ◽  
Donna M. Weber ◽  
Michael Wang ◽  
Sheeba K. Thomas ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Lactate Dehydrogenase ◽  
Prognostic Value ◽  
Intensive Therapy ◽  
Serum Lactate ◽  
Response To Therapy ◽  
Stage Iii ◽  
Serum Lactate Dehydrogenase ◽  
Survival Times ◽  
The Impact

8093 Background: In patients with symptomatic multiple myeloma, the clinical features, responses to treatment, and survival times vary. Well established predictors of survival include the International Staging System (ISS), cytogenetic abnormalities, and response to therapy. Long recognized has been the association of high serum lactate dehydrogenase (LDH) with advanced disease and shorter survival. We focused here on the impact of high LDH on staging and prognosis in order to guide the role of recent advances in therapy. Methods: We evaluated 1,247 patients with newly diagnosed, symptomatic myeloma from 10/74 to 7/11. Our goal was to determine the prognostic value of high LDH (>300 IU/L) in relation to ISS stage. We also compared the frequencies of anemia, hypercalcemia, and response to therapy in patients with high LDH with those of patients with Stage III disease and normal LDH values. Results: All 1,139 patients with normal LDH lived significantly longer than the 108 patients with elevated values (47 vs. 16 months, p <.01). LDH was elevated in 9% of all patients, but in 2%, 6%, and 18% of patients with ISS-I, II, and III disease, respectively. Their survival times were also significantly shorter than those of comparable patients in each stage with normal LDH (table). Among the 108 patients with high LDH, the frequencies of hemoglobin <8.5 g/dl (54 vs. 41%, p=.03), and serum calcium>11.5 mg/dl (41 vs. 27%, p<.01) were significantly higher than those of 292 patients with Stage III disease and normal LDH, and the frequency of response to therapy was less (40 vs. 62%, p<.01). Conclusions: Serum lactate dehydrogenase provides a convenient and dependable prognostic indicator in patients with multiple myeloma. An elevated LDH value indicates a poor prognosis regardless of ISS stage, confirming the report by Gkotzamanidou, Terpos, and Dimopoulos et al, and should be included in the definition of stage III disease. Such patients require rapid control of disease with sequential combinations of effective drugs and intensive therapy in order to improve their outcome. [Table: see text]

Preoperative serum lactate dehydrogenase levels in colorectal and gastric cancer: a hospital-based case–control study

2013 ◽  
Vol 7 (1) ◽  
pp. 131-137 ◽  
Author(s):  
Ioannis D Kostakis ◽  
Aristeidis G Vaiopoulos ◽  
Anastassios Philippou ◽  
Athanasios G Papavassiliou ◽  
Michael Koutsilieris ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lactate Dehydrogenase ◽  
Case Control Study ◽  
Case Control ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Preoperative Serum ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document